Guidance for Conducting Human Gene Transfer Research at UK

Overview:
Human gene transfer (HGT) research is defined by federal regulations as “the deliberate transfer into human research participants of either:

1. Recombinant nucleic acid molecules, or DNA or RNA derived from recombinant nucleic acid molecules, or
2. Synthetic nucleic acid molecules, or DNA or RNA derived from synthetic nucleic acid molecules, that meet any one of the following criteria:
   a. Contain more than 100 nucleotides; or
   b. Possess biological properties that enable integration into the genome (e.g., cis elements involved in integration); or
   c. Have the potential to replicate in a cell; or
   d. Can be translated or transcribed.”

HGT research poses many scientific, medical, ethical, social, safety and methodological challenges not shared by other forms of human research. As such, a number of regulatory requirements must be satisfied before the initiation of any human research involving gene transfer. Principal Investigators (PIs) must navigate a complex process of multiple reviews and approvals at both federal and institutional levels. This help guide serves to assist PIs in initiating a human gene transfer protocol.

Federal Requirements:

- **Food and Drug Administration (FDA) [http://www.fda.gov/cber/](http://www.fda.gov/cber/)**
  
  The Center for Biologics Evaluation and Research (CBER) regulates human gene therapy products (products that introduce genetic material into the body to replace faulty or missing genetic material) based upon the Public Health Service Act and the Federal Food Drug and Cosmetic Act. It is the responsibility of the pharmaceutical sponsor or principal investigator to file an Investigational New Drug (IND) application for each new investigational agent intended for human study in accordance with 21 CFR 312.

  The FDA has published the “Guidance for Human Somatic Cell Therapy and Gene Therapy”, containing guidelines and recommendations regarding the clinical use of gene products.

- **NIH-OBA / Recombinant DNA Advisory Committee (RAC) [http://oba.od.nih.gov/rdna/rdna.html](http://oba.od.nih.gov/rdna/rdna.html)**
  
  The Recombinant DNA Advisory Committee (RAC) of the NIH-Office of Biotechnology Activities (OBA) is responsible for the review of research protocols involving the deliberate transfer of recombinant DNA, or DNA or RNA derived from recombinant DNA, into human subjects (human gene transfer), funded by NIH or that take place at an institution receiving NIH funds. Human gene transfer protocols must be submitted to NIH as described in Appendix M, Points to Consider in the Design and Submission of Protocols for the Transfer of Recombinant DNA Molecules into One or More Research Participants, of the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. The process outlined in Appendix M must be completed prior to review by the NIH RAC. The NIH review process is open to the public so proprietary information should be withheld.

  Upon receipt of the complete human gene transfer protocol, it is sent to RAC members for an initial review. During this preliminary protocol review period, RAC members may request additional information or clarification regarding your submission and sometimes may make specific comments/suggestions regarding protocol design, informed consent document, etc. At the end of the preliminary review process, RAC members will determine if the protocol raises important scientific, safety, medical, ethical or social issues that warrant an in-depth public review.

  In-depth, public review of a protocol occurs when…

  1. OBA Director initiates review following a recommendation for review by at least three (3) RAC members or another federal agency; or
  2. The NIH Director initiates that review.

  You will be notified within fifteen (15) working days of submitting all the information required under Appendix M of the
Guidance for Conducting Human Gene Transfer Research at UK

outcome of the initial review process. If your protocol is selected for public review, you will be asked to make a 15-20 minute presentation about your protocol at the scheduled RAC meeting.

The outcome of public RAC review is a series of recommendations and advice from experts in the field. It does not entail a formal approval of the proposed protocol. The recommendations will be captured in a summary letter prepared by OBA and sent within ten (10) working days of completion of the RAC meeting. The summary letter will also be sent to the IRB and IBC reviewing your protocol, in addition to the FDA.


Institutional Requirements:

- Institutional Biosafety Committee (IBC)

The IBC is responsible for reviewing recombinant DNA and biohazardous research conducted at or sponsored by the institution, regardless of funding source or location of research, for compliance with the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules and other appropriate guidelines and University policies, to assess the safety of the research and identify any potential risk to public health of the environment.

You must submit your protocol to the IBC for review via UK's online registration software. For more information regarding the online submission process, visit http://ehs.uky.edu/docs/pdf/bio_ibc_registration_0001.pdf In addition to completing the online protocol registration process, you must also submit the following:

- RAC Summary Letter
- Clinical Protocol
- Investigational Brochure
- Staff training video or presentation (if applicable)
- Other proprietary information as required
- Informed Consent document
- Patient training materials

Once all issues have been addressed satisfactorily, the protocol will be granted "provisional approval" and a memo indicating such will be sent to the PI. The "provisional approval" memo must be submitted to the IRB as part of the IRB application materials. Please note HGT protocols must be reviewed by the IBC and granted provisional approval prior to IRB submission. Once IRB approval is obtained, a copy of the IRB approved consent form, patient training materials, and IRB approval letter must be submitted to the Biological Safety Department. Once all necessary documents have been received, a full IBC approval memo will be issued to the PI.

- Institutional Review Board (IRB) http://www.research.uky.edu/ori/

The IRB is a federally mandated committee responsible for review of research studies involving human subjects. Its purpose is to ensure that proper safeguards are in place to protect human subjects enrolled in research studies.

PIs must submit a Medical IRB Full Review Application available online (http://www.research.uky.edu/ori/MedicalFullReviewApplication.htm). There are seven sections to the IRB application. Depending on the nature of the research, some sections will apply while others will not. The PI must review each section to determine applicability to the research and include the appropriate forms in the IRB application submission.

The concepts of HGT research are often difficult for potential participants to understand. As such, NIH/OBA has developed guidance on the issue of informed consent in gene transfer studies (http://oba.od.nih.gov/oba/rac/ic/index.html). This additional guidance is not part of the NIH Guidelines, or an amendment to Appendix M, but rather should be used by PIs as a resource in developing an informed consent document for a HGT
Guidance for Conducting Human Gene Transfer Research at UK

Prior to submission of IRB application material to the IRB for review, the protocol must be reviewed by the IBC and granted provisional approval.

The Medical IRB meets approximately six times per month. There is no deadline for submission of applications. Protocols are assigned on a “first come, first served” basis, and will be placed on the next available agenda.

Full reviews require that the PI attend the meeting at which the application is reviewed. A review date is assigned to the protocol at the time of submission. The PI must notify the Office of Research Integrity (859-257-9428) if he/she is not available on the assigned review date.

After Institutional IBC and IRB Approval…

1. Obtain all committee approval letters
2. Verification of local oversight and approval (IBC and IRB) must be submitted to the NIH/OBA
3. Within 20 working days of enrolling the first research participant, the PI must send a report to NIH/OBA in accordance with Appendix M-I-C-I of the NIH Guidelines, including:
   - Copy of informed consent document approved by the Institutional Review Board (IRB);
   - Copy of the protocol approved by the Institutional Biosafety Committee (IBC) and IRB;
   - Copy of the final IBC approval from the clinical trial site;
   - Copy of the final IRB approval
   - Brief written report that includes the following information: (1) how the investigator(s) responded to each of the RAC’s recommendations on the protocol (if applicable); and (2) any modifications to the protocol as required by the FDA;
   - Applicable NIH grant number(s);
   - FDA Investigational New Drug Application (IND) number; and
   - Date of initiation of trial.

After trial begins…

Please note - The FDA and NIH share reporting deadlines. The University of Kentucky IBC and IRB share reporting deadlines.

<table>
<thead>
<tr>
<th>Annual Reporting</th>
<th>Amendments</th>
<th>Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDA</td>
<td>In accordance with 21 CFR 312.33, submit within 60 days of the anniversary date the IND went into effect.</td>
<td>Submit to FDA in accordance with 21 CFR 312.30.</td>
</tr>
<tr>
<td>NIH/OBA</td>
<td>In accordance with Appendix M-I-C-3 of the NIH Guidelines, submit within 60 days of the anniversary date the IND went into effect.</td>
<td>No Submission Required.</td>
</tr>
<tr>
<td>IBC</td>
<td>Complete the IBC Annual Renewal form online <a href="http://topaz.uky.edu">http://topaz.uky.edu</a>.</td>
<td>IBC approval is required for all amendments prior to implementation. Submit to IBC an amendment form online <a href="http://topaz.uky.edu">http://topaz.uky.edu</a>.</td>
</tr>
<tr>
<td>IRB</td>
<td>Complete the IRB Continuation Review</td>
<td>Submit a</td>
</tr>
</tbody>
</table>
### Guidance for Conducting Human Gene Transfer Research at UK

<table>
<thead>
<tr>
<th>Report and return to the Office of Research Integrity</th>
<th>Modification Request Form and include short summary letter signed by PI.</th>
<th>Reporting Form to the Office of Research Integrity, 315 Kinkead Hall, 0057. For more information, see the UK Policy on Prompt Reporting</th>
</tr>
</thead>
</table>

### Additional Resources:

- [http://www.fda.gov/cber/](http://www.fda.gov/cber/)
- [NIH Guidelines for Research Involving Recombinant DNA Molecules](http://ehs.uky.edu/biosafety/)
- [Frequently Asked Questions about the NIH Review Process for Human Gene Transfer Trials](http://www.research.uky.edu/ori/)